Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Amarantus Bioscience Holdings (AMBS) Message Board

As of June 27, 2019 the number of shares outstandi

Message Board Public Reply | Private Reply | Keep | Replies (1)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 30067
(Total Views: 753)
Posted On: 07/01/2019 7:22:35 PM
Avatar
Posted By: freegriff
Re: Bornet #27885
As of June 27, 2019 the number of shares outstanding of our Common Stock was: 258,051,454

Number of shares in the Public Float6: 125,086,151 as of date: 06/13/2019
Total number of shareholders of record: 205 as of date: 06/13/2019

Behold the history of dilution (goes beyond 2019)!!!! Since September 2017, 180M shares have been diluting us for services, settlements, conversions etc. Most recently...

1/8/2019 New 12,250,000 New Common Services Restricted
2/5/2019 New 2,000,000 Common $0.028 Services Restricted
5/15/2019 Cancel 55,000 Common retire
5/24/2019 New 1,761,494 Common $0.0114 Debt Conversion Unrestricted
5/31/2019 New 4,000,000 Common $0.023 Services Restricted
6/4/2019 New 2,777,778 $0.009 Debt Conversion Unrestricted
6/10/2019 Cancel 1195 Series I $1,000 No GHS Exchange to Debt
6/11/2019 New 1,000,000 Common $0.020 Services Restricted

The common conversions are to unidentified parties. The Series I is of course to GHS. This new debt, along with all other debt (Total approximately $18M) from the Legacy Convertibles or Toxics or whatever you want to call (Lincoln Park, Delafield, Anson, Dominion,, KDL Holdings, Gemini, BMI, Greentree, Roger Challen, Vivacitas, International Infusion) is totaled and described to be converted through Reg A with an expiration of 3/31/2020. Not exactly an indefinite like the previous letter to shareholders said.

If I'm reading this correctly, GC seems to have, at some point, bought out 64% of the series H, 87% of the series E, 100% of the series F. This is important because as of this filing, the only preferred class shares that exist are B,E,F, H. I thought Geral already owned all the B, but that isn't listed.








(4)
(0)




Amarantus Bioscience Holdings (AMBS) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us